International Ophthalmology

, Volume 30, Issue 4, pp 345–351 | Cite as

Photodynamic therapy for choroidal neovascularization in young adult patients

  • Rita Ehrlich
  • Michal Kramer
  • Irit Rosenblatt
  • Dov Weinberger
  • Karin Mimouni
  • Ethan Priel
  • Ruth Axer-Siegel
Original Paper

Abstract

We report our experience with photodynamic therapy (PDT) in the treatment of choroidal neovascularization (CNV) in young adult patients. This was a retrospective study of young adults with CNV treated with PDT. Data collected included age, diagnosis, type and size of CNV, number of treatments, visual outcome, and side effects. Ten patients (11 eyes) were included in the study (mean age 27.2 ± 13.3 years). Etiologies included multifocal choroiditis (3 eyes), idiopathic CNV (5 eyes), central serous chorioretinopathy (1 eye), and toxoplasma (2 eye). The mean number of treatments was 2 ± 0.7 and the mean follow-up time was 13.1 ± 9.5 months. Initial visual acuity (VA) ranged from 20/25 to 20/1,200 (mean logMAR 0.6 ± 0.5), and improved to 20/20 to 20/250 (mean logMAR 0.46 ± 0.4) (P = 0.51). Of the four eyes that received additional treatment with oral steroids, one of which also received intravitreal bevacizumab (Avastin) injections, all had visual acuity improvement of 2 or more lines, while only two of seven eyes that received PDT alone showed such improvement. PDT can improve visual outcome in a subgroup of young patients with subfoveal CNV especially when supplemented with oral steroid and bevacizumab injections.

Keywords

Choroidal neovascularization Young Photodynamic therapy 

References

  1. 1.
    Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomised clinical trials—TAP report 1. Arch Ophthalmol 117:1329–1345Google Scholar
  2. 2.
    Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomised clinical trials-TAP report 2. Arch Ophthalmol 119:198–207PubMedGoogle Scholar
  3. 3.
    Vertoporfin In Photodynamic (VIP) Therapy Study Group (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 131:541–560CrossRefGoogle Scholar
  4. 4.
    Blinder KJ, Blumenkranz MS, Bressler NM et al (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP Report No. 3. Ophthalmology 110:667–673CrossRefPubMedGoogle Scholar
  5. 5.
    Wachtlin J, Heimann H, Behme T et al (2003) Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefe’s Arch Clin Exp Ophthalmol 241:899–906CrossRefGoogle Scholar
  6. 6.
    Ergun E, Tittl M, Stur M (2004) Photodynamic therapy with verteporfin in subfoveal choroidal neovascularization secondary to central serous chorioretinopathy. Arch Ophthalmol 122:37–41CrossRefPubMedGoogle Scholar
  7. 7.
    Browning AC, Chung AK, Ghanchi F, United Kingdom PDT Users Group et al (2005) Verteporfin photodynamic therapy of choroidal neovascularization in angioid streaks: one-year results of a prospective case series. Ophthalmology 112:1227–1231CrossRefPubMedGoogle Scholar
  8. 8.
    Fong KCS, Thomas D, Inzerillo D et al (2008) Photodynamic therapy combined with systemic corticosteroids for choroidal neovascularization secondary to punctuate inner choroidopathy. Eye 22:528–533CrossRefPubMedGoogle Scholar
  9. 9.
    Axer-Siegel R, Ehrlich R, Weinberger D et al (2004) Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age at onset. Am J Ophthalmol 138:602–607CrossRefPubMedGoogle Scholar
  10. 10.
    Rosenfeld PJ, Brown DM, Heier JS, MARINA Study Group et al (2006) Ranibizumab for neovascular age related macular degeneration. N Engl J Med 355:1419–1431CrossRefPubMedGoogle Scholar
  11. 11.
    Brown DM, Kaiser PK, Michels M, ANCHOR Study Group et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444CrossRefPubMedGoogle Scholar
  12. 12.
    Postelmans L, Pasteels B, Coquelet P et al (2004) Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females. Am J Ophthalmol 138(5):803–808CrossRefPubMedGoogle Scholar
  13. 13.
    Schlötzer-Schrehardt U, Viestenz A, Naumann GO et al (2002) Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 240:748–757CrossRefPubMedGoogle Scholar
  14. 14.
    Wachtlin J, Behme T, Heimann H et al (2003) Concentric retinal pigment epithelium atrophy after a single photodynamic therapy. Graefes Arch Clin Ophthalmol 241:518–521CrossRefGoogle Scholar
  15. 15.
    Grossniklaus HE, Green WR (1992) Pathologic findings in pathologic myopia. Retina 12:127–133CrossRefPubMedGoogle Scholar
  16. 16.
    Kramer M (2005) Photodynamic therapy for inflammatory CNV: do we know enough? Ocul Immunol Inflamm 13:331–333CrossRefPubMedGoogle Scholar
  17. 17.
    Rogers AH, Duker JS, Nichols N et al (2003) Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults. Ophthalmology 110:1315–1320CrossRefPubMedGoogle Scholar
  18. 18.
    Leslie T, Lois N, Christopoulou D et al (2005) Photodynamic therapy for inflammatory choroidal neovascularization unresponsive to immunosuppression. Br J Ophthalmol 89:147–150CrossRefPubMedGoogle Scholar
  19. 19.
    Postelmans L, Pasteels B, Coquelet P et al (2005) Photodynamic therapy for subfoveal classic choroidal neovascularization related to punctate inner choroidopathy (PIC) or presumed ocular histoplasmosis-like syndrome (POHS-like). Ocul Immunol Inflamm 13:361–366CrossRefPubMedGoogle Scholar
  20. 20.
    Hogan A, Behan U, Kilmartin DJ (2005) Outcomes after combination photodynamic therapy and immunosuppression for inflammatory subfoveal choroidal neovascularisation. Br J Ophthalmol 89:1109–1111CrossRefPubMedGoogle Scholar
  21. 21.
    Spaide RF, Freund KB, Slakter J et al (2002) Treatment of subfoveal choroidal neovascularization associated with multifocal choroiditis and panuveitis with photodynamic therapy. Retina 22:545–549CrossRefPubMedGoogle Scholar
  22. 22.
    Chan WM, Lai TY, Lau TT et al (2008) Combined photodynamic therapy and intravitreal triamcinolone for choroidal neovascularization secondary to punctuate inner choroidopathy or of idiopathic origin: one-year results of a prospective series. Retina 28:71–80CrossRefPubMedGoogle Scholar
  23. 23.
    Luthra S, Narayanan R, Marques LE et al (2006) Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 26:512–518CrossRefPubMedGoogle Scholar
  24. 24.
    Mauget-Faÿsse M, Mimoun G, Ruiz-Moreno JM et al (2006) Verteporfin photodynamic therapy for choroidal neovascularization associated with toxoplasmic retinochoroiditis. Retina 26:396–403CrossRefPubMedGoogle Scholar
  25. 25.
    Spaide RF, Martin ML, Slakter J et al (2002) Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfin. Am J Ophthalmol 134:62–68CrossRefPubMedGoogle Scholar
  26. 26.
    Lam A, Lee HC, Ho AC et al (2006) Photodynamic therapy in young patients. Ophthalmic Surg Lasers Imaging 37(3):182–189PubMedGoogle Scholar
  27. 27.
    Chan WM, Lam DS, Wong TH et al (2003) Photodynamic therapy with vertoporfin for subfoveal idiopathic choroidal neovascularization: one-year results from a prospective case series. Ophthalmology 110:2395–2402CrossRefPubMedGoogle Scholar
  28. 28.
    Mandal S, Garg S, Venkatesh P et al (2007) Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization. Arch Ophthalmol 125:1487–1492CrossRefPubMedGoogle Scholar
  29. 29.
    Gomi F, Nishida K, Oshima Y et al (2007) Intravitreal bevacizumab for idiopathic choroidal neovascularization after previous injection with posterior subtenon triamcinolone. Am J Ophthalmol 143:507–509CrossRefPubMedGoogle Scholar
  30. 30.
    Chan WM, Lai TY, Liu DT et al (2007) Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 143:977–983CrossRefPubMedGoogle Scholar
  31. 31.
    Adán A, Mateo C, Navarro R et al (2007) Intravitreal bevacizumab (avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina 27:1180–1186CrossRefPubMedGoogle Scholar
  32. 32.
    Nguyen QD, Shah SM, Hafiz G et al (2008) Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age related macular degeneration. Am J Ophthalmol 145:257–266CrossRefPubMedGoogle Scholar
  33. 33.
    Mansour AM, Mackensen F, Arevalo JF et al (2008) Intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol 146:410–416CrossRefPubMedGoogle Scholar
  34. 34.
    Fine HF, Zhitomirsky I, Freund KB et al (2009) Bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization in multifocal choroiditis. Retina 29:8–12CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Rita Ehrlich
    • 1
  • Michal Kramer
    • 1
    • 2
    • 3
  • Irit Rosenblatt
    • 1
    • 2
  • Dov Weinberger
    • 1
    • 2
    • 3
  • Karin Mimouni
    • 1
    • 2
  • Ethan Priel
    • 2
  • Ruth Axer-Siegel
    • 1
    • 2
    • 3
  1. 1.Department of OphthalmologyRabin Medical CenterPetah TiqvaIsrael
  2. 2.Mor Institute for Medical DataBnei BerakIsrael
  3. 3.Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael

Personalised recommendations